1,461
Views
0
CrossRef citations to date
0
Altmetric
Gastroenterology

Multi-omics analysis reveals the interaction of gut microbiome and host microRNAs in ulcerative colitis

, , , , , , & show all
Article: 2261477 | Received 25 Jul 2023, Accepted 18 Sep 2023, Published online: 29 Sep 2023
 

Abstract

Background

Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal tract that co-occurs with gut microbiota dysbiosis; however, its etiology remains unclear. MicroRNA (miRNA)-microbiome interactions play an essential role in host health and disease.

Methods

To investigate the gut microbiome and host miRNA profiles in colitis, we used a Dextran Sulfate Sodium (DSS)-induced ulcerative colitis (UC) model. Metagenomic sequencing and metabolome profiling were performed to explore typical microbiota and metabolite signatures in colitis, whereas mRNA and miRNA sequencing were used to determine differentially expressed miRNAs and their target genes in the inflamed colon.

Results

A total of 986 miRNAs were identified between the two groups, with 41 upregulated and 21 downregulated miRNAs in colitis mice compared to the control group. Notably, the target genes of these significantly altered miRNAs were primarily enriched in the immune and inflammation-related pathways. Second, LEfSe analysis revealed bacterial biomarkers distinguishing the two groups, with significantly higher levels of commonly encountered pathogens such as Escherichia coli and Shigella flexneri in the UC group, whereas beneficial species such as Bifidobacterium pseudolongum were more abundant in the control group. Microbiota metabolites histamine, N-acetylhistamine, and glycocholic acid were found to be downregulated in colitis mice. Spearman correlation further revealed the potential crosstalk between the microbiota profile and colonic miRNA, revealing the possibility of microbiome–miRNA interactions involved in IBD development.

Conclusions

Our data reveal the relationships between multi-omic features during UC and suggest that targeting specific miRNAs may provide new avenues for the development of effective miRNA-based therapeutics.

This article is part of the following collections:
Gut Microbiome in Inflammatory Bowel Disease

Authors contributions

L.M. and C.H. performed the experiments, analyzed the data, prepared the figures, and wrote the manuscript; H.Y. and Q.C. participated in the experiments; W.L. collected samples; Z.W., J.W., and Y.X. contributed to the study concept, design, and revised the manuscript.

Ethics statement

All animal procedures were approved by the Institutional Animal Care and Use Committee of the Zhejiang Academy of Agricultural Sciences (2018ZAASLA20).

Disclosure statement

The authors report no conflict of interest.

Data availability statement

The sequencing data were submitted to the NCBI SRA database using PRJNA795271 and PRJNA795830. The data supporting the findings of this study are available from the corresponding author upon request.

Additional information

Funding

This work was supported by the Postdoctoral Science Foundation of China under Grant 2021M702905, National Natural Science Foundation of China under Grant 31972999, and State Key Laboratory for Managing Biotic and Chemical Threats to the Quality and Safety of Agro-Products under Grant 2021DG700024-ZZ202208 and 2021DG700024-KF202208.